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BACKGROUND: Patients with primary biliary cholangitis who have an inadequate
response to therapy with ursodeoxycholic acid are at high risk for disease
progression. Fibrates, which are agonists of peroxisome proliferator-activated
receptors, in combination with ursodeoxycholic acid, have shown potential benefit in
patients with this condition.
METHODS: In this 24-month, double-blind, placebo-controlled, phase 3 trial, we
randomly assigned 100 patients who had had an inadequate response to
ursodeoxycholic acid according to the Paris 2 criteria to receive bezafibrate at a
daily dose of 400 mg (50 patients), or placebo (50 patients), in addition to continued
treatment with ursodeoxycholic acid. The primary outcome was a complete
biochemical response, which was defined as normal levels of total bilirubin, alkaline
phosphatase, aminotransferases, and albumin, as well as a normal prothrombin
index (a derived measure of prothrombin time), at 24 months.
RESULTS: The primary outcome occurred in 31% of the patients assigned to
bezafibrate and in 0% assigned to placebo (difference, 31 percentage points; 95%
confidence interval, 10 to 50; P<0.001). Normal levels of alkaline phosphatase were
observed in 67% of the patients in the bezafibrate group and in 2% in the placebo
group. Results regarding changes in pruritus, fatigue, and noninvasive measures of
liver fibrosis, including liver stiffness and Enhanced Liver Fibrosis score, were
consistent with the results of the primary outcome. Two patients in each group had
complications from end-stage liver disease. The creatinine level increased 5% from
baseline in the bezafibrate group and decreased 3% in the placebo group. Myalgia
occurred in 20% of the patients in the bezafibrate group and in 10% in the placebo
group.
CONCLUSIONS: Among patients with primary biliary cholangitis who had had an
inadequate response to ursodeoxycholic acid alone, treatment with bezafibrate in
addition to ursodeoxycholic acid resulted in a rate of complete biochemical response
that was significantly higher than the rate with placebo and ursodeoxycholic acid
therapy. (Funded by Programme Hospitalier de Recherche Clinique and Arrow
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